Positions for Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

In Q4 2018 Intercept Pharmaceuticals Inc (NASDAQ:ICPT) big money sentiment increased to 1.4, revealed SEC filings. That’s up 0.15, from 2018Q3’s 1.25. 87 hedge funds increased or opened new holdings, while 62 sold and reduced their stakes in Intercept Pharmaceuticals Inc so the sentiment improved. These funds own 19.17 million shares, that’s up from 18.21 million shares in 2018Q3. Funds holding Intercept Pharmaceuticals Inc in top 10 was flat from 2 to 2 for the same number . 18 Investors Sold All; 44 Reduced Holdings; 47 increased holdings while 40 hedge funds bought holdings.

Largest Intercept Pharmaceuticals Inc Shareholders

Bb Biotech Ag owns 575,719 shares in Intercept Pharmaceuticals Inc as of Q4 2018. As of Q4 2018, 207,657 shares of Intercept Pharmaceuticals Inc are owned by Elk Creek Partners Llc. Altrinsic Global Advisors Llc reported 277,944 shares. Sarissa Capital Management Lp revealed 54,000 shares position in Intercept Pharmaceuticals Inc. The Texas-based fund Qcm Cayman Ltd. holds 2,181 shares or 0.9% of their portfolio.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.The firm is valued at $3.35 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Currently it has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

ICPT is reaching $112.93 during the last trading session, after increased 1.78%.Currently Intercept Pharmaceuticals, Inc. is uptrending after 77.42% change in last March 15, 2018. ICPT has 427,382 shares volume. ICPT outperformed the S&P 500 by 73.05%.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)’s earnings report is anticipated on May, 14., Faxor reports. Analysts forecast $-2.44 EPS, which is $0.78 up or 24.22 % from 2018’s $-3.22 EPS. After $-2.97 EPS was published previous quarter, analysts now see EPS growth of -17.85 % for Intercept Pharmaceuticals, Inc..

Hudock Capital Gru Limited Liability Company owns 50 shs. Pub Employees Retirement Association Of Colorado holds 0% or 3,548 shs. Moreover, California Pub Employees Retirement System has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 29,865 shs. Guggenheim Cap Ltd Liability Company reported 27,763 shs. Jane Street Ltd Com holds 0.01% or 23,841 shs in its capital. Eulav Asset Mgmt invested in 73,000 shs or 0.37% of the stock. Daiwa Grp invested 0% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Susquehanna Int Grp Incorporated Limited Liability Partnership holds 53,788 shs. Tekla Cap Mngmt Limited Liability Co holds 0.06% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 13,348 shs. State Bank Of America Corp De holds 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 96,542 shs. Deutsche National Bank & Trust Ag has invested 0.03% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Fisher Asset Management Lc has invested 0.01% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Principal Fincl Grp Inc reported 19,914 shs. Mackay Shields Lc stated it has 7,561 shs or 0.01% of all its holdings. Chicago Equity Ptnrs Ltd Liability Corp holds 8,930 shs or 0.04% of its capital.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

A total of 14 analysts rate Intercept Pharmaceuticals (NASDAQ:ICPT) as follows: 11 “Buy”, 2 “Hold” and 1 “Sell”. Тherefore 79% are bullish. (NASDAQ:ICPT) has 33 ratings reports on 15 Mar 2019 according to StockzIntelligence. On Tuesday, February 19 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Buy” rating by Roth Capital. On Wednesday, February 20 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Hold” rating by RBC Capital Markets. On Friday, February 22 the rating was initiated by Leerink Swann with “Sell”. On Wednesday, January 30 the stock has “Market Outperform” rating by JMP Securities. On Tuesday, February 19 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, February 19 the rating was maintained by Wedbush with “Outperform”. On Friday, March 1 the stock has “Buy” rating by Oppenheimer. The stock rating was maintained by Raymond James with “Buy” on Thursday, February 28. On Thursday, February 28 the firm earned “Hold” rating by RBC Capital Markets. The stock rating was maintained by Needham with “Buy” on Tuesday, February 19.

For more Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news released briefly go to: Benzinga.com, Seekingalpha.com, Benzinga.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Analyst: Intercept (NASDAQ:ICPT)’s NASH Drug Could Launch Sans Competition After Gilead (NASDAQ:GILD) Trial Failure – Benzinga” released on February 13, 2019, “Genfit In NASH And Market Assessment: What’s New? – Seeking Alpha” on March 07, 2019, “Benzinga’s Top Upgrades, Downgrades For March 1, 2019 – Benzinga” with a publish date: March 01, 2019, “$35 Billion Market! Positive Clinical Trial! Yet Shares Are Down? – Nasdaq” and the last “Notable Friday Option Activity: ICPT, C, CBS – Nasdaq” with publication date: March 01, 2019.